Drug Profile
Infliximab biosimilar - Curaxys
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Curaxys
- Developer Curaxys; University of Cadiz
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ankylosing spondylitis; Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Sarcoidosis; Uveitis
Most Recent Events
- 24 Jun 2015 Discontinued for Ankylosing spondylitis in Spain (unspecified route)
- 24 Jun 2015 Discontinued for Crohn's disease in Spain (unspecified route)
- 24 Jun 2015 Discontinued for Psoriasis in Spain (unspecified route)